Skip to content
Snippets Groups Projects
results.tsx 45.9 KiB
Newer Older
Liliana Sanfilippo's avatar
Liliana Sanfilippo committed

import {  H4 } from "../components/Headings";
Kathleen Susat's avatar
Kathleen Susat committed

Liliana Sanfilippo's avatar
Liliana Sanfilippo committed
import { Section, Subesction } from "../components/sections";
import { useTabNavigation } from "../utils/TabNavigation";
Vera Köhler's avatar
Vera Köhler committed
import { H5 } from "../components/Headings";
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
import { useNavigation } from "../utils";
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
import { DownloadLink } from "../components/Buttons";
Kathleen Susat's avatar
Kathleen Susat committed
import { ThreeVertical, TwoHorizontal, TwoVertical } from "../components/Figures";
Liliana Sanfilippo's avatar
Liliana Sanfilippo committed
import { ResTable } from "../components/Table";
import { headercols, resultdata } from "../data/results-table";

export function Results() {
  useTabNavigation();
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
  const {goToPagesAndOpenTab} = useNavigation ();
Isabell Alexandra Guckes's avatar
pc  
Isabell Alexandra Guckes committed
  const {goToPageAndScroll} = useNavigation();

  return (
    <>
Liliana Sanfilippo's avatar
Liliana Sanfilippo committed
      <Section title="Abstract" id="Abstract">
Kathleen Susat's avatar
Kathleen Susat committed
         <p>For the prime editing of cystic fibrosis (CF), we on the one hand optimized a prime editing complex and on the other hand developed an efficient delivery system. For testing, we set up cell culture with model cell lines as well as primary cells taken from team members and a patient.</p>
<p>For editing, we first compared different existing prime editors (pCMV-PE2, pLV-PE_CO-Mini, pCMV-PE6c) and constructed a reporter plasmid simulating the CFTR context. In addition and to further enhance the editing process, we designed various pegRNAs tailored to our construct incorporating features such as silent edits, for a lower mismatch repair, and a 3′ stabilizing stem loop (tevropQ1). The aim was to identify the most effective pegRNA for our specific target, which is why pegRNA especially for CFTR F508del mutation were designed.</p> 
Kathleen Susat's avatar
Kathleen Susat committed

Kathleen Susat's avatar
Kathleen Susat committed
<p>As proof of concept, we transfected these constructs in HEK-293 and CFTR mutated CFB41o- cells and observed significant prime editing of our reporter via fluorescence microscopy. We identified the PE6c editor and our pegRNA variant 4 as optimal. This resulted in our Best New Basic Part, PEAR_CFTR. Furthermore, we extended our approach to primary human nasal epithelial cells generated from our own nasal epithelial cells through nasal swabs. By cultivating them in Air Liquid Culture (ALI) and Apical-Our Organoids, we successfully tested our technologies in vitro, mimicking the in vivo situation.</p> 
Kathleen Susat's avatar
Kathleen Susat committed

Kathleen Susat's avatar
Kathleen Susat committed
<p>Furthermore, we successfully designed and cloned novel nickases of Fanzor, which is special because of its smaller size and eukaryotic origin. This serves as valuable tool for future genome editing applications. </p>
Kathleen Susat's avatar
Kathleen Susat committed

Kathleen Susat's avatar
Kathleen Susat committed
<p>For delivery, lipid nanoparticles (LNPs) are a highly effective and versatile delivery system, valued for their larger cargo capacity, biocompatibility, and ability to protect RNA from degradation. To deliver our Prime Editing construct as mRNA, we optimized a Selective ORgan Targeting (SORT) LNP for targeted delivery to the lungs by using the cationic helper lipid DOTAP and encapsulating a stable Chitosan-RNA complex, achieving significant breakthroughs in transfection of in vitro lung epithelial cells. </p>
Kathleen Susat's avatar
Kathleen Susat committed

Kathleen Susat's avatar
Kathleen Susat committed
<p>We began by testing three different LNP formulations, starting with the Cayman LipidLaunc LNP-102 Exploration Kit. We confirmed by fluorescence microscopy, where Minicircle DNA effectively transfected HEK293 cells. Further experiments with the Corden LNP Stater Kit #2 failed to achieve successful transfection, likely due to increased cytotoxicity from a more cytotoxic PEG component. </p>
Kathleen Susat's avatar
Kathleen Susat committed

Kathleen Susat's avatar
Kathleen Susat committed
<p>Our successful formulation was a lung-specific SORT LNP, which demonstrated excellent stability, as confirmed by zeta potential measurements. Dynamic light scattering (DLS) analysis revealed an optimal particle size of 200 nm, aligning with literature and supporting the ability of the LNPs to penetrate deep lung regions via inhalation. Flow cytometry analysis showed that the SORT LNP had 14 times higher transfection efficiency compared to control formulations. Moreover, an MTT cytotoxicity assay revealed that the SORT LNP, along with Cayman LNPs, exhibited the lowest cytotoxicity, thanks to the use of low-molecular-weight PEG components. </p>
Kathleen Susat's avatar
Kathleen Susat committed

Kathleen Susat's avatar
Kathleen Susat committed
<p>To further enhance the stability and sustainability of the LNPs for inhalation, we incorporated chitosan-RNA complexes, which provide thermal stability and protect RNA from degradation by RNases. Integration of these complexes into the SORT LNP resulted in a lung-specific delivery platform. Using this system, we achieved highly efficient transfection of a bronchial cell line from a cystic fibrosis patient (CFBE41o- with F508del mutation), demonstrating the potential of this approach for targeted gene delivery to lung epithelial cells. These results highlight the remarkable efficiency, stability and specificity of our optimized SORT LNP formulation, positioning it as a promising platform for lung-specific genetic therapies. </p>
Liliana Sanfilippo's avatar
Liliana Sanfilippo committed
      </Section>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
      <Section title="Experimental Design" id="ExpDes">
      <Subesction title="Proof of Concept" id="Results1">
Kathleen Susat's avatar
Kathleen Susat committed
          <H4 text="Proof-of-concept"/>
Kathleen Susat's avatar
Kathleen Susat committed
          <H5 text="Workflow"/>
          <p>The prepared pDAS12124-preedited plasmid serves as a positive control to validate the success of the experiment. A technical control with the pZMB938 plasmid confirms successful transfection of the cells. In the main part of the experiment, pDAS12489-2in1 and pCMV-PE2 are co-transfected. Successful transfection is visualised by GFP signals.</p> 
Kathleen Susat's avatar
Kathleen Susat committed
          <H5 text="Conclusion"/>
Kathleen Susat's avatar
Kathleen Susat committed
          <p>The microscopy data validates our proof of concept. Compared to our internal positive control, pDAS12124-preedited (see Figure 1), less cells co-transfected with pDAS12489 and pCMV-PE2 (see Figure 1) showed fluorescence. Contrary to our expectations, the technical transfection control with pZMB938 showed lower transfection efficiency. All negative controls showed no fluorescence.</p>
Kathleen Susat's avatar
Kathleen Susat committed
          <ThreeVertical
Kathleen Susat's avatar
Kathleen Susat committed
            description="Microscopy of HEK293 72h post transfection with lipofectamine 2000. Transfection with technical positive control pZMB938, internal positive control pDAS12124-preedited, co-transfection of pDAS12489 with pCMV-PE2, NTC, PE2 as control and pDAS12489 as control. All controls are negative and both positve controls as well as pDAS12489+pCMV-PE2 show fluorescence signals."
Kathleen Susat's avatar
Kathleen Susat committed
            num={1}
            pic1="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild1-1.png"
            pic2="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild1-2.png"
            pic3="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild1-3.png"
          />
Kathleen Susat's avatar
Kathleen Susat committed
          <H4 text="Transfection optimization"/>
Kathleen Susat's avatar
Kathleen Susat committed
          <H5 text="Workflow"/>
          <p>To optimise transfection efficiency, different dilutions and concentrations of DNA were used to find the best transfection conditions.</p> 
Kathleen Susat's avatar
Kathleen Susat committed
          <H5 text="Conclusion"/>
Kathleen Susat's avatar
Kathleen Susat committed
          <p>All 4 different transfection conditions were done with pZMB938 and showed good results, but best result were done when lipofectamine 2000 was diluted 1:10 and 1000 ng DNA was transfected.</p> 
Kathleen Susat's avatar
Kathleen Susat committed
          <TwoVertical
            description="Microscopy of HEK293 72h post transfection with lipofectamin 2000. Transfection with 1:10 or 1:25 diluted lipofectamine and 800 ng or 1000 ng of out technical positive control pZMB938."
Kathleen Susat's avatar
Kathleen Susat committed
            num={2}
            pic1="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild2-1.png"
            pic2="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild2-2.png"
          />
Kathleen Susat's avatar
Kathleen Susat committed
          <H5 text="Workflow"/>
          <p>Transfection with Lipofectamine 3000 was performed because of the probably better performance and transfection rate. The prepared pDAS12124-preedited plasmid serves as a positive control to validate the success of the experiment. A technical control with the pZMB938 plasmid confirmed successful transfection of the cells as before. In the main part of the experiment, pDAS12489-2in1 and pCMV-PE2 were co-transfected. Successful transfection and prime editing was detected by GFP signals.</p> 
Kathleen Susat's avatar
Kathleen Susat committed
          <H5 text="Conclusion"/>
Kathleen Susat's avatar
Kathleen Susat committed
          <p>Internal control and technical control showed higher transfection efficiency then in previous experiments, therefore transfection with lipofectamine 3000 seems to be more efficient than transfection with lipofectamine 2000. The fluorescence of pDAS12189+pCMV-PE2 was still quite low. All negative  controls are showed no fluorescence.</p>
Kathleen Susat's avatar
Kathleen Susat committed
          <ThreeVertical
Kathleen Susat's avatar
Kathleen Susat committed
          description="Microscopy of HEK293 72h post transfection with lipofectamine 2000. Transfection with technical positive control pZMB938, internal positive control pDAS12124-preedited, co-transfection of pDAS12489 with pCMV-PE2, NTC, PE2 as control and pDAS12489 as control. All controls are negative and both positve controls as well as pDAS12489+pCMV-PE2 show fluorescence signals."
Kathleen Susat's avatar
Kathleen Susat committed
          num={3}
          pic1="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild3-1.png"
          pic2="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild3-2.png"
          pic3="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild3-3.png"
          />
Kathleen Susat's avatar
Kathleen Susat committed
          <H5 text="Workflow"/>
          <p>Again a preliminary test with the technical positive control was conducted potentially optimize our transfection protocol and to train the handling.</p> 
Kathleen Susat's avatar
Kathleen Susat committed
          <H5 text="Conclusion"/>
          <p>The results of the test were not as good as expected. Nearly no transfection efficiency was visible. This could be due to too old HEK293 cells</p> 
Kathleen Susat's avatar
Kathleen Susat committed
          <TwoVertical
            description="Microscopy of HEK293 72h post transfection with lipofectaine 3000. Transfection of 500 ng or 1000 ng of our technical positive control pZMB938 with 1 µl or 1.5 µl of lipofectamine 3000."
Kathleen Susat's avatar
Kathleen Susat committed
            num={4}
            pic1="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild4-1.png"
            pic2="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild4-2.png"
          />
Kathleen Susat's avatar
Kathleen Susat committed
          <H5 text="Workflow"/>
          <p>HEK cells were thawed and another prelimary test was conducted. In this test two different transfection agents were used (Lipofectamine 3000 & CaCl2) to check which one is better suited for our experiments. The literature uses lipofectamine 3000 but CaCl2 transfection is much cheaper.</p> 
Kathleen Susat's avatar
Kathleen Susat committed
          <H5 text="Conclusion"/>
Kathleen Susat's avatar
Kathleen Susat committed
          <p>Both transfections are working out well but the efficiency of the lipofectamine transfection was much higher.</p>
Kathleen Susat's avatar
Kathleen Susat committed
          <div className="figure-wrapper">
              <figure>
                    <img src="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild5.png" style={{height: "10%", width: "auto"}}/>
                    <figcaption> <b>Figure 5.</b>Microscopy of HEK293 72h post transfection with lipofectamine 3000 with 1000 ng or 1500 ng technical positive control pZMB938. Both transfections show fluorescence signals.</figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
              </figure>
          </div>          
          <TwoVertical
Kathleen Susat's avatar
Kathleen Susat committed
            description="Microscopy of HEK293 72h post transfection with CaCl2 with 500 ng, 1000 ng or 1500 ng pZMB938. All transfections show fluorescence signals."
            num={6}
Kathleen Susat's avatar
Kathleen Susat committed
            pic1="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild6-1.png"
            pic2="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild6-2.png"
          />
Kathleen Susat's avatar
Kathleen Susat committed
          <H5 text="Workflow"/>
          <p>One last time the transfection of pDAS12189+pCMV-PE2 was conducted. Although our proof-of-concept already showed successful editing the first time, we repeated the experiment to get better transfection efficiency.</p> 
Kathleen Susat's avatar
Kathleen Susat committed
          <H5 text="Conclusion"/>
Kathleen Susat's avatar
Kathleen Susat committed
          <p>The transfection efficiency was much better. Our proof-of-concept was working correctly. The reporter system pDAS12189 only led to production of a fluorescent signal when co transfected with a prime editing complex as pCMV-PE2.</p> 
Kathleen Susat's avatar
Kathleen Susat committed
          <TwoVertical
Kathleen Susat's avatar
Kathleen Susat committed
            description="Microscopy of HEK293 72h post transfection with lipofectamine 2000. Transfection with technical positive control pZMB938, internal positive control pDAS12124-preedited, co-transfection of pDAS12489 with pCMV-PE2, NTC, PE2 as control and pDAS12489 as control. All controls are negative and both positve controls as well as pDAS12489+pCMV-PE2 show fluorescence signals."
            num={7}
Kathleen Susat's avatar
Kathleen Susat committed
            pic1="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild7-1.png"
            pic2="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild7-2.png"
          />
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
      </Subesction>
      <Subesction title="Mechanism" id="Results2">
Kathleen Susat's avatar
Kathleen Susat committed
          <H4 text="Initial testing of pegRNAs and Evaluation of silent edits"/>
          <H5 text="Workflow"/>
          <p>With this experiment we wanted to compare the efficiency of pegRNAs with and without silent edits.</p> 
          <H5 text="Conclusion"/>
          <p>The Flow Cytometry analysis shows that pegRNA without silent edits (pegRNA1) had a 2.05 times higher transfection efficiency than pegRNA with silent edits (pegRNA2).</p>         
Kathleen Susat's avatar
Kathleen Susat committed
          <TwoHorizontal 
Kathleen Susat's avatar
Kathleen Susat committed
            description="Flow cytometry analysis of pegRNAs with and without silent edits. Histograms of cell count applied against fluorescence intensity of healthy HEK293 cells (left) with untransfected cells as negative control, pDAS12124 pre-edited as internal positive control and pegRNAs with (pegRNA1) and without (pegRNA2) silent edits 72 h after transfection. The portion of fluorescent cells is normalized to the internal positive control (right)."
Kathleen Susat's avatar
Kathleen Susat committed
            pic1="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/se-nose.png"
            pic2="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild8.png"
Kathleen Susat's avatar
Kathleen Susat committed
          />
Kathleen Susat's avatar
Kathleen Susat committed
          <H4 text="Screening of pegRNA variants"/>
          <H5 text="Workflow"/>
          <p>Cotransfection of pPEAR_CFTR and PE2 and also 1 of the 14 pegRNAs to compare the transfection efficiency of all of our designed pegRNAs.</p> 
          <H5 text="Conclusion"/>
          <p>The pegRNAs lead to differing amounts of cells showing fluorescence, which, assuming comparable transfection efficiencies, indicates varying prime editing efficiency. The pegRNA7 showed the highest transfection efficiency (see Figure 9).</p>
Liliana Sanfilippo's avatar
Liliana Sanfilippo committed
          <ResTable cols={headercols} data={resultdata}/>
Kathleen Susat's avatar
Kathleen Susat committed
          <div className="figure-wrapper">
              <figure>
                    <img src="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild9.png" style={{height: "10%", width: "auto"}}/>
Kathleen Susat's avatar
Kathleen Susat committed
                    <figcaption> <b>Figure 9.</b>Percentage of fluorescent HEK293 cells 72 h after transfection with various pegRNAs (pegRNA1-14) normalized to pDAS12124 pre-edited as internal positive control as result of flow cytometry analysis.</figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
              </figure>
          </div>
Kathleen Susat's avatar
Kathleen Susat committed
          <H4 text="Application lung epithelial cell lines"/>
          <H5 text="Workflow"/>
          <p>We tried to transfect CFBE41o- cells with pDAS12124-preedited, our internal positive control, to check if a transfection of this cell line is possible. Furthermore we tried to co transfect the CFBE41o- with pPEAR_CFTR, PE6c and pegRNA4.</p> 
          <H5 text="Conclusion"/>
          <p>Transfection of CFBE41o- with pDAS12124-preedited was successful (see Figure 10). After 24 hours a successful co transfection of pPEAR_CFTR with PE6c and pegRNA4 was visible, although the transfection efficiency was really bad (see Figure 10).</p>
Kathleen Susat's avatar
Kathleen Susat committed
          <TwoVertical
           description="Microscopy results after 24h or 48h. Transfection of pDAS12124-preedited with lipofectamine 3000 was successfully done in CFBE41o- cell line and visible after 48h. CFBE41o- cell line was transfected with pDAS-IDT with Lipofectamine 3000 and afterwards with LNPs including PE6c and pegRNA4 and was after 24h fluorescence visible."
Kathleen Susat's avatar
Kathleen Susat committed
           pic1="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild10-1.png"
           pic2="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild10-2.png"
           />
Kathleen Susat's avatar
Kathleen Susat committed
          <p>Moreover transfection was conducted in human nasal epithelial cells (hNECs) in Air-liquid interface cultures as well as apical-out airway organoids (see Figure 11). No fluorescence was visible. </p>
          <TwoVertical
           description="Microscopy of HEK 72h post transfection with lipofectamine 3000. Co-transfection of pPEAR_CFTR with PE6c and pegRNA4. Both show no fluorescence signals."
           num={11}
           pic1="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/ali-tr.png"
           pic2="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/aoao-tr.png"
           />
Kathleen Susat's avatar
Kathleen Susat committed
          <H4 text="Comparison of prime editing complexes PE2 and PE_CO-Mini"/>
          <H5 text="Workflow"/>
          <p>pCMV-PE2 was co transfected with pDAS12489 and pCMV-PE_CO-Mini was co transfected with pDAS12489 in HEK293 cell line.</p> 
          <H5 text="Conclusion"/>
Kathleen Susat's avatar
Kathleen Susat committed
          <p>The Flow Cytometry results show that transfection with pCMV-PE2 as the prime editing complex had editing efficiency of 52.90% when normalized on pDAS12124-preedited. When pCMV-PE_CO-Mini was used as a prime editing complex it had a transfection efficiency of 2.54% (see Figure 12, 13).</p>
Kathleen Susat's avatar
Kathleen Susat committed
          <TwoVertical
           description="Microscopy of HEK 72h post transfection with lipofectamine 3000. Co-transfection of pDAS12489 with pCMV-PE2 or pDAS12489 with LV-PE_CO-Mini. Both show fluorescence signals."
Kathleen Susat's avatar
Kathleen Susat committed
           num={12}
Kathleen Susat's avatar
Kathleen Susat committed
           pic1="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild11-1.png"
           pic2="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild11-2.png"
           />
           <div className="figure-wrapper">
              <figure>
Kathleen Susat's avatar
Kathleen Susat committed
                    <img src=" Flow Cytometry analysis to compare prime editing complexes PE2 and PE_CO-Mini. Histograms of cell count applied against fluorescence intensity of healthy HEK293 cells (left) with untransfected cells as negative control, pDAS12124 pre-edited as internal positive control 72 h after transfection." style={{height: "10%", width: "auto"}}/>
                    <figcaption> <b>Figure 13. </b>Flow Cytometry analysis to compare prime editing complexes PE2 and PE_CO-Mini</figcaption>
              </figure>
          </div>
          <H5 text="Workflow"/>
          <p>We compared the 3 different Prime Editing complexes (pCMV-PE2, pCMV-PE2_CO-Mini & pCMV-PE6c) to check which one has the best transfection efficiency.</p> 
          <H5 text="Conclusion"/>
Kathleen Susat's avatar
Kathleen Susat committed
          <p>The Flow Cytometry measurement shows the fluorescence rate cells co-transfected with pDAS12489 and pCMV-PE6c as a prime editing complex. The editing efficiency off PE6c was by far the highest (81.88%) (see Figure 14, 15). The efficiency was 1.55 higher than the efficiency when pCMV-PE2 was used as prime editing complex (see Figure 13).</p>
Kathleen Susat's avatar
Kathleen Susat committed
          <div className="figure-wrapper">
              <figure>
                    <img src="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild13.png" style={{height: "10%", width: "auto"}}/>
Kathleen Susat's avatar
Kathleen Susat committed
                    <figcaption> <b>Figure 14. </b>Microscopy of HEK293 72h post transfection with lipofectamine 3000 and co transfection with pCMV-PE6c and pDAS12489.</figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
              </figure>
          </div>
          <TwoHorizontal
Kathleen Susat's avatar
Kathleen Susat committed
          description="Flow cytometry analysis for evaluation of performance of prime editor variants. Histograms of cell count applied against fluorescence intensity of healthy HEK293 cells (left) with untransfected cells as negative control, pDAS12124 pre-edited as internal positive control and PE6c, PE2 and PE2C 72 h after transfection. The portion of fluorescent cells is normalized to the internal positive control (right)."
          num={15}
Kathleen Susat's avatar
Kathleen Susat committed
          pic1="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/pe2-pe-co-pe6c.png"
          pic2="https://static.igem.wiki/teams/5247/photos/facs-results-mechanism/bild12.png"
          /> 
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
      </Subesction >
      <Subesction  title="Delivery" id="Results3">
Max Luca Beckmann's avatar
Max Luca Beckmann committed
      <H4 text="RNA Synthesis"/>
      <div className="row align-items-center">
        <div className="col">
          <figure>
            <img src="https://static.igem.wiki/teams/5247/delivery/results/rna-gel-final.png"/>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
            <figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
              <b>Figure 1. </b>
              Gel of Denaturing RNA Gel Electrophoresis for mRNA synthesized from pcDNA 3.1 eYFP indicating successful RNA synthesis. Lane 1: Low Range Ribo Ruler, Lane 2: FLuc Control Template, Lane 3: Negative Control, Lane 4-9 mRNA from pcDNA 3.1 eYFP.
Max Luca Beckmann's avatar
Max Luca Beckmann committed
            </figcaption>
          </figure>
        </div>
        <div className="col">
Kathleen Susat's avatar
Kathleen Susat committed
          <p>We began by synthesizing mRNA <i>in vitro</i> using a plasmid with a eYFP reporter from Addgene (pcDNA 3.1 eYFP) before proceeding with the synthesis of our approximately 6000 bp prime editing RNA. This was done to test the transfection efficiency and compatibility of our lipid nanoparticles (LNPs). The synthesis was successful, yielding an average of 1400 ng/µl of purified mRNA from 1 µg of plasmid DNA determined by Nanodrop measurement (data not shown). The size and integrity of the synthesized RNA were confirmed using a denaturing RNA gel, where we expected to see a product of 900 nucleotides. As anticipated, a strong and prominent band corresponding to this size was observed (Figure X). This mRNA was subsequently used in further LNP formulations with RNA.</p>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
        </div>
      </div>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
      <H4 text="Cayman LNP"/>
            <div className="row align-items-center">
            <div className="col">
Kathleen Susat's avatar
Kathleen Susat committed
            <p>Next, we formulated the LNPs using the Cayman LipidLaunch™ LNP-102 Exploration Kit after the manufacturers protocol. The initial assembly attempt was unsuccessful, as no cloudy, bluish solution formed after mixing the lipids. Additionally, transfection of HEK293 cells with LNPs containing nucleic acids did not produce any fluorescence. After consulting with expert <a onClick={() => goToPagesAndOpenTab('radukic', '/human-practices')}>Dr. Marco Radukic</a> and adjusting our LNP formulation and transfection protocols, specifically by pre-acidifying the OptiMEM medium, we were able to successfully assemble and transfect the LNPs. We also got from him Minicircle DNA from <a href="https://www.plasmidfactory.com/custom-dna/minicircle-dna/" title="PlasmidFactory" >PlasmidFactory</a> as a small plasmid carrying an eYFP gene and easy to transform, by that serving as a positive control in our experiments. Upon pipetting the components together, the solution immediately turned cloudy and bluish, indicating successful LNP formation (Figure X).</p>
            </div>
            <div className="col">
              <figure>
                <img src="https://static.igem.wiki/teams/5247/delivery/results/caymanlnpblue.webp"/>
                <figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
                <b>Figure X. </b>
                  Cayman LNP Formation indicated by blue color and turbidity. Mini DNA = Minicircle DNA from PlasmidFactory.
                  </figcaption>
              </figure>
            </div>
          </div>
          <H5 text="Transfection"/>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
            <p>To evaluate the efficiency of transfection, we performed fluorescence microscopy (Leica DMI6000 B at 20x magnification) on HEK293 cells transfected with LNP-formulated DNA and mRNA of pcDNA 3.1 eYFP, Minicircle DNA as technical positive control and LNP without cargo.</p>
Kathleen Susat's avatar
Kathleen Susat committed
            <p>24 h, 48 h and 72 h post-transfection, we observed in the conditions with Lipofectamine alone, or combined with DNA or RNA, no fluorescence, indicating unsuccessful transfection. Similarly, no fluorescence was seen in cells treated with LNPs alone or in combination with DNA or RNA. When LNPs were combined with Minicircle DNA, clear fluorescence was observed, indicating successful transfection and expression of our eYFP reporter under this condition (figure X). However, a strong background fluorescence from the OptiMEM medium was observed, complicating the analysis.</p>
            <p>Overall, among all the tested conditions, the LNP formulation with Minicircle DNA was the only combination that resulted in noticeable fluorescence, suggesting it to be the most effective transfection method for HEK293 cells in this experiment.</p>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
            <figure>
Liliana Sanfilippo's avatar
Liliana Sanfilippo committed
              <img src="https://static.igem.wiki/teams/5247/delivery/results/precyse/cayman.png"/>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
              <figcaption>
Liliana Sanfilippo's avatar
Liliana Sanfilippo committed
                <b>Figure 18. </b>
                Overlay of phase contrast and fluorescence microscopic images of transfected HEK293 cells at 20x magnification after 72 h post-transfection with different Cayman LNP formulations recorded with Leica DMI6000 B. For Lipofectamine (Lipo) + Minicircle DNA (Mini DNA) only the fluorescence image is shown.
Max Luca Beckmann's avatar
Max Luca Beckmann committed
              </figcaption>
Liliana Sanfilippo's avatar
Liliana Sanfilippo committed
            </figure>
          <H5 text="SEM"/>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
          <div className="row align-items-center">
            <div className="col">
Kathleen Susat's avatar
Kathleen Susat committed
              <p>Scanning Electron Microscopy (SEM) (Phenom ProX, Thermo Fisher) was employed by us to examine the morphology and surface characteristics of Cayman LNPs. The SEM images revealed that the LNPs displayed a generally spherical morphology with a relatively smooth surface (Figure X). The average particle size was approximately 200 nm. However, a heterogeneous distribution of particle sizes was observed, with some larger, round structures present. These larger structures could potentially indicate aggregated LNPs.</p>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
            </div>
            <div className="col">
              <figure>
                <img src="https://static.igem.wiki/teams/5247/delivery/results/screenshot-2024-10-01-200629.png" alt="CayREM" style={{maxHeight: "200pt"}}/> 
Max Luca Beckmann's avatar
Max Luca Beckmann committed
                <figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
                  <b>Figure X.</b>
                  SEM image of Cayman LNPs (10,000x magnification) with Topography mode.                </figcaption>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
              </figure>
            </div>
          </div>
          <p>While many particles retained their structural integrity, the presence of these aggregates suggests that, under certain conditions, the LNPs may tend to cluster. It is important to note that for SEM analysis, the samples were dried and observed under vacuum, which probably have affected the structure and shape of the LNPs. This preparation process can introduce artifacts that would not typically be present in solution and should be considered when interpreting the results. Additionally, the contrast under vacuum conditions was too low to reliably distinguish the LNPs with sufficient detail. It provided a useful initial glimpse into the world of nanoparticles. Further complementary techniques will be needed for a more accurate and detailed characterization.</p>
Vera Köhler's avatar
Vera Köhler committed
          <H4 text="Corden LNP"/>
Kathleen Susat's avatar
Kathleen Susat committed
          <H5 text="Transfection"/>
          <p>Fluorescence microscopy with the Leica DMI6000 B microscope at 20x magnification was  by us on HEK293 cells transfected with LNPs containing pcDNA 3.1 eYFP DNA and mRNA. Minicircle DNA served as the positive control, while LNPs without cargo acted as the negative control. Cells were imaged at 24 h, 48 h, and 72 h post-transfection.</p>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
          <div className="row align-items-center">
        <div className="col">
          <figure>
            <img src="https://static.igem.wiki/teams/5247/delivery/results/whatsapp-image-2024-09-24-at-12-57-59.jpeg"/>
            <figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
              <b>Figure X. </b>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
              Turbidity after components of the Corden LNP have been pipetted together indicates particle formation.            </figcaption>
          </figure>
        </div>
        <div className="col">
Kathleen Susat's avatar
Kathleen Susat committed
              <p>During the preparation of the LNPs, the solution became turbid and bluish, indicating successful nanoparticle formation (Figure X). This was further confirmed by cryo-EM analysis, which revealed the presence of well-formed LNPs. Despite the successful formation of LNPs, no detectable fluorescence was observed in the cells treated with LNPs containing pcDNA 3.1 eYFP DNA or mRNA at any of the measured time points, indicating that transfection did not occur under these conditions.</p>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
            </div>
        </div>
Kathleen Susat's avatar
Kathleen Susat committed
        <p>Quantitatively, none of the LNP-treated samples showed significant fluorescence, indicating a failure in transfection. The lack of fluorescence in all experimental groups, except the positive control, suggests either insufficient uptake of the LNPs by the cells or a failure in expression of the YFP reporter. </p>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
        <figure>
Kathleen Susat's avatar
Kathleen Susat committed
              <img src="Insert URL here"/>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
              <figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
                <b>Figure X. </b>
                Fluorescence microscopic images of transfected HEK293 cells at 20x magnification after 48 h post-transfection with different Corden LNP formulations recorded with Leica DMI6000 B.
Max Luca Beckmann's avatar
Max Luca Beckmann committed
              </figcaption>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
          </figure>
        <H5 text="Cryo-EM"/>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
        <p>Cryo-EM (cryogenic electron microscopy) as a form of transmission electron microscopy (TEM) was performed by us using a JEOL JEM-2200FS electron microscope (JEOL, Freising, Germany) operating at 200kV, equipped with a cold field emission electron gun. The sample preparation and imaging were carried out at cryogenic temperatures, which allowed for the visualization of LNPs in their native hydrated state.</p>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
        <div className="row align-items-center">
          <div className="col">
            <figure>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
              <img src="https://static.igem.wiki/teams/5247/delivery/results/corden-lnp.jpg"/>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
              <figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
                <b>Figure X. </b>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
                Cryo-EM image of Corden LNPs.
Max Luca Beckmann's avatar
Max Luca Beckmann committed
              </figcaption>
            </figure>
          </div>
          <div className="col">
Kathleen Susat's avatar
Kathleen Susat committed
            <p>The images reveal the presence of spherical LNP structures with an approximate size of 100 nm (Figure X). The LNPs appear well-formed, with uniform morphology, indicating successful nanoparticle formation. In addition to individual particles, some larger, round structures were also observed, which could represent aggregated LNPs. These aggregations are a common phenomenon in LNP systems and could be attributed to interactions between particles under certain conditions.</p>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
          </div>
        </div>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
        <p>While Cryo-EM provides valuable insights into the morphology and size distribution of the LNPs, there are some limitations to this technique. The imaging process involves cryogenic freezing and exposure to high-energy electron beams, which can potentially induce minor structural artifacts. Furthermore, the thinness of the sample may limit contrast, making it difficult to fully distinguish between different LNP populations or their internal structures. Despite these limitations, Cryo-EM still offers a high-resolution view of the LNPs in their near-native state, providing essential information about their size and shape.</p>
Kathleen Susat's avatar
Kathleen Susat committed
        <H4 text="Sort LNP"/>
        <H5 text="Transfection"/>
Kathleen Susat's avatar
Kathleen Susat committed
          <p>Text :D</p>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
            <figure>
Kathleen Susat's avatar
Kathleen Susat committed
              <img src="Insert URL here"/>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
              <figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
                <b>Figure X. </b>
                Description here
Max Luca Beckmann's avatar
Max Luca Beckmann committed
              </figcaption>
            </figure>
        <H5 text="Flow cytometry"/>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
          <div className="row align-items-center">
Kathleen Susat's avatar
Kathleen Susat committed
          <p>We performed flow cytometries analysis 72 h post-transfection to evaluate the transfection efficiency of the SORT LNP in HEK293. The relative percentage of fluorescent cells was determined by measuring the percentage of FITC-A+ cells, followed by normalization to the negative control and fold change calculation.</p>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
            <div className="col">
              <figure>
              <img src="https://static.igem.wiki/teams/5247/delivery/results/sortlnp-facs.png" alt="SORTFACS" style={{maxHeight: "200pt"}}/> 
Max Luca Beckmann's avatar
Max Luca Beckmann committed
                <figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
                 <b>Figure X. </b>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
                 Percentage of fluorescent cells (FITC-A+) performed 72 h post-transfection of SORT LNP in HEK293. Mean +/- SEM for n=3. For statistics one-way ANOVA was performed. 
Max Luca Beckmann's avatar
Max Luca Beckmann committed
                </figcaption>
              </figure>
            </div>
            <div className="col">
Kathleen Susat's avatar
Kathleen Susat committed
              <p>The SORT LNP-transfected sample carrying Minicircle DNA exhibited a significant increase in fluorescence compared to the lipofectamine transfection of Minicircle DNA, with approximately 14 times more fluorescent cells compared to the lipofectamine-transfected sample (Figure a). This substantial difference indicates that the transfection efficiency with LNPs is markedly higher than with lipofectamine, demonstrating the superior performance of our LNP formulation in delivering nucleic acids to HEK cells.</p>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
            </div>
          </div>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
          <H5 text="Zeta Potential"/>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
            <div className="row align-items-center">
              <div className="col">
Kathleen Susat's avatar
Kathleen Susat committed
                <p>We measured both the particle size distribution and the Zeta potential using the Nanotrack Wave II. We could assume that the particles exhibit a polarized Zeta potential, which is sufficient to provide electrostatic stabilization, thereby preventing aggregation and maintaining particle stability. For effective targeting of lung cells which have negatively charged surfaces, a negative polarity is desirable meaning the LNP is positively charged, so there can be electrostatic attraction to lung epithelial cells. We were able to show that our SORT LNP has these properties regardless of the load. Furthermore we could <a href="https://chem.libretexts.org/Bookshelves/Analytical_Chemistry/Physical_Methods_in_Chemistry_and_Nano_Science_(Barron)/02%3A_Physical_and_Thermal_Analysis/2.05%3A_Zeta_Potential_Analysis" title="StabZeta" >determine the stability via the Zeta potential</a>. In detail the mean of the Zeta potential lays at 16.2 mV for the SORT LNP with Minicircle DNA as cargo, indicating incipient stability, at 59.45 mV for the SORT LNP with pcDNA 3.1 eYFP as cargo, indicating good stability and at 88.22 mV for the SORT LNP without cargo indicating excellent stability (Figure z). The good stability of the SORT LNP with pcDNA 3.1 eYFP is crucial for our purposes, as it ensures effective delivery and performance. In contrast, the stability of the LNPs with Minicircle DNA can be considered secondary, as it primarily serves as a positive transfection control and is not central to our main objectives.</p>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
              </div>
              <div className="col">
                <figure>
                  <img src="https://static.igem.wiki/teams/5247/delivery/results/sort-zeta.webp"/>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
                  <figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
                    <b>Figure X. </b>
                    Zeta potential of SORT LNP with different cargos measured with Nanotrack Wave II indicating varying degrees of stability but most important good stability for the SORT LNP loaded with pcDNA 3.1 eYFP (LNP DNA). Mean +/- SEM for n=5. For statistics one-way ANOVA was performed.                  </figcaption>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
                </figure>
              </div>
            </div>
            <div className="row align-items-center">
          <div className="col">
            <figure>
              <img src="https://static.igem.wiki/teams/5247/delivery/results/screenshot-2024-10-01-204938.png"/>
              <figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
                <b>Figure X. </b>
                Size distribution for the SORT LNP with different cargos weighted by scattering intensity measured with Nanotrack Wave II.
              </figcaption>
            </figure>
          </div>
          <div className="col">
Kathleen Susat's avatar
Kathleen Susat committed
            <p>The size distribution for all three samples shows a predominantly monomodal, yet broad, distribution with diameters ranging between 50 nm and 700 nm, with the peak of the distribution lying between 150 nm and 200 nm (Figure d). SORT LNPs without DNA exhibited larger radii, with a peak around 300 nm. The SORT LNP containing Minicircle DNA suggests the presence of larger aggregates with diameters exceeding 1 µm. The likely reason for this variable particle size distribution, despite loading with different types of DNA, could be attributed to the manufacturing method. Since the LNPs were not produced using an extruder but rather via dialysis, this is highly plausible.</p>
          </div>
          </div>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
          <H5 text="Cryo-EM"/>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
            <div className="row align-items-center">
                <div className="col">
Kathleen Susat's avatar
Kathleen Susat committed
                  <p>Cryo-EM analysis was also performed of SORT LNPs by us with the same JEOL JEM-2200FS microscope at 200kV, allowing visualization of LNPs in their native hydrated state. The images show spherical LNP structures around 100 nm, with some larger aggregates also present (data not shown). These aggregates likely result from interactions between particles due to the non-extrusion-based preparation method, which may explain the variability in particle size. Additionally, particles potentially representing different LNP populations or overlapped structures with low contrast were observed (Figure X). The low sample concentration likely contributed to the limited number of visible particles.</p>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
                </div>
                <div className="col">
                  <figure>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
                   <img src="https://static.igem.wiki/teams/5247/delivery/results/sortcryoem.png"/>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
                   <figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
                      <b>Figure X. </b>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
                      Cryo-EM image of SORT LNPs. The different colored outlines indicate different size populations of LNPs.
Max Luca Beckmann's avatar
Max Luca Beckmann committed
                    </figcaption>
                  </figure>
                </div>
              </div>
Kathleen Susat's avatar
Kathleen Susat committed
              <p>Overall, while the Cryo-EM data confirm the presence and general morphology of LNPs that also fall within the diameter range specified by Wang et al. for SORT LNPs at smaller than 200 nm [link]. The variability in size and the presence of aggregates highlight potential areas for optimization, such as refining sample concentration and preparation methods to achieve more consistent particle formation.</p>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
              <H5 text="DLS"/>
          <p>We used Dynamic Light Scattering (DLS) to assess the size distribution of our SORT LNPs by measuring the fluctuations in scattered light due to particle motion. The hydrodynamic diameter was calculated using the Stokes-Einstein equation, considering the diffusion coefficient, temperature, and viscosity of the medium.</p>
            <div className="row align-items-center">
              <div className="col">
                <figure>
                  <img src="https://static.igem.wiki/teams/5247/delivery/results/sort-dls.webp"/>
                  <figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
                    <b>Figure X. </b>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
                    Results for hydrodynamic radius determination by DLS Measurements for our SORT LNP, indicating a radius of approximately 100 nm.
                  </figcaption>
                </figure>
              </div>
              <div className="col">
Kathleen Susat's avatar
Kathleen Susat committed
                <p>The results showed a hydrodynamic diameter of SORT LNPs yielding an average radius of approximately 100 nm (Figure X). These findings are consistent with our previous applied size determination methods, such as Zeta potential and Cryo-EM, which also indicated similar particle dimensions in appropriate range for our research and medical applications.</p>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
              </div>
            </div>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
          <H5 text="MTT Assay"/>
            <div className="row align-items-center">
              <div className="col">
                <figure>
                 <img src="https://static.igem.wiki/teams/5247/fanzor/sort-mtt.webp"/>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
                  <figcaption>
Kathleen Susat's avatar
Kathleen Susat committed
                  <b>Figure X. </b>
                  MTT Assay of LNPs from all iterations performed on HEK293 including Triton as negative control and untreated cells as positive control. Mean +/- SEM for n=6. For statistics one-way ANOVA was performed.                  </figcaption>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
                </figure>
              </div>
              <div className="col">
                {/* <p>In order to evaluate the <a onClick={() => goToPageAndScroll ('Biosafety2', '/safety')}>biosafety</a> of our lung-specific LNPs, particularly concerning the choice of <a onClick={() => goToPagesAndOpenTab({collapseId: 'Col1', path: '/engineering', tabId: 'delivery' })}>PEG</a> - known to cause cytotoxicity issues - we performed MTT assays using HEK293 cells with various LNP formulations. The results demonstrated that the Cayman LNP achieved 74.90% viability and SORT LNP showed 75.01% viability, exhibiting lower cytotoxicity due to the inclusion of DMG-PEG, a less cytotoxic PEG variant compared to mPEG-2000-DSPE, which resulted in 66.69% viability in the Corden LNP (Figure t). These findings prove we made the best decision by choosing the SORT LNP as the least cytotoxic LNPs.</p> */}
Kathleen Susat's avatar
Kathleen Susat committed
                <p>In order to evaluate the <a onClick={() => goToPageAndScroll ('Biosafety2', '/safety')}>biosafety</a> of our lung-specific LNPs, particularly concerning the choice of PEG - known to cause cytotoxicity issues - we performed MTT assays using HEK293 cells with various LNP formulations. The results demonstrated that the Cayman LNP achieved 74.90% viability and SORT LNP showed 75.01% viability, exhibiting lower cytotoxicity due to the inclusion of DMG-PEG, a less cytotoxic PEG variant compared to mPEG-2000-DSPE, which resulted in 66.69% viability in the Corden LNP (Figure t). These findings prove we made the best decision by choosing the SORT LNP as the least cytotoxic LNPs.</p>
Max Luca Beckmann's avatar
Max Luca Beckmann committed
              </div>
            </div>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
      </Subesction >
      <Subesction  title="PreCyse" id="Results4">
Liliana Sanfilippo's avatar
Liliana Sanfilippo committed
          <H4 text="Goals"/>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
          <p>text</p> 
Liliana Sanfilippo's avatar
Liliana Sanfilippo committed
          <H4 text="Workflow"/>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
          <p>text</p> 
          <H4 text="Conclusion"/>
          <p>text</p> 
      </Subesction >
      <Subesction  title="Patch Clamp" id="Results5">
Isabell Alexandra Guckes's avatar
pc  
Isabell Alexandra Guckes committed
          <p>To validate our gene editing approach by prime editing of CFTR F508del delivered to lung cells via SORT LNPs, we planned to use <a onClick={() => goToPageAndScroll ('Patch Clamp', '/materials-methods')}>Patch Clamp</a> as a downstream method. Our goal was to detect the restored conductance of the repaired CFTR by this electrophysiological method. This was made possible through the assistance of the <a onClick={() => goToPagesAndOpenTab('patchclamp', '/human-practices')}>Cellular Neurophysiology research group</a> at our university.</p>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
          <H4 text="Initial Measurements"/>
            <div className='row align-items-center'>
              <div className='col'>
                <figure> 
                  <img src="https://static.igem.wiki/teams/5247/photos/results/patchclamp/pc1.webp" alt="PC1" style={{maxHeight: "300pt"}}/> 
                  <figcaption> 
Kathleen Susat's avatar
Kathleen Susat committed
                  <b>Figure 1. </b> 
                  Current density of HEK293, HEK293T CFTR WT and HEK293T CFTR F508del showing significant differences of both HEK293T cell lines compared to HEK293 but no significant differences between them. For statistics one-way ANOVA was performed.
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
                  </figcaption> 
                </figure> 
              </div>
              <div className='col'>
Kathleen Susat's avatar
Kathleen Susat committed
                <p>In our first set of experiments, we measured current density in <a onClick={() => goToPageAndScroll ('Cell Culture', '/materials-methods')}>HEK293T CFTR wild-type (WT) and HEK293T F508del</a> cell lines, comparing them with regular HEK293. The results demonstrated significant differences in chloride ion conductance, with the CFTR-expressing cell lines showing enhanced conductivity compared to HEK293 (Figure 1). However, a drawback was that we did not observe any significant differences between the HEK293T CFTR WT and F508del cell line. This was unexpected, as the F508del mutation typically leads to a knockdown of the CFTR protein, impairing chloride ion transport through the CFTR channel.</p>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
              </div>
            </div>
            <H4 text="Further Validation and Challenges"/>
            <div className='row align-items-center'>
            <div className='col'>
Kathleen Susat's avatar
Kathleen Susat committed
              <p>In light of these results, we improved our experimental setup and performed additional validation experiments. Unfortunately, the repeated measurements yielded similar outcomes, confirming the absence of a significant difference between the two CFTR-expressing cell lines (Figure 2). This finding led us to consult with the research group at <a onClick={() => goToPagesAndOpenTab('mattijsvisit', '/human-practices')}>KU Leuven</a>, who established these cells lines. Although they had not conducted similar Patch Camp measurements, they suggested an alternative approach using Ussing Chamber measurements. This technique, unlike Patch Camp, does not rely on single-cell measurements but rather examines the ion currents across the entire cell monolayer, which may provide a more comprehensive view of CFTR functionality.</p>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
              </div>
              <div className='col'>
                <figure> 
                  <img src="https://static.igem.wiki/teams/5247/photos/results/patchclamp/pc2.webp" alt="PC1" style={{maxHeight: "300pt"}}/> 
                  <figcaption> 
Kathleen Susat's avatar
Kathleen Susat committed
                  <b>Figure 2. </b> 
                  Repeated validation of current density measurements in HEK293T CFTR WT and HEK293T CFTR-F508del, showing consistent results with the initial experiment. For statistics one-way ANOYA was performed.
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
                  </figcaption> 
                </figure> 
              </div>
            </div>
            <H4 text="Next Steps"/>
Isabell Alexandra Guckes's avatar
pc  
Isabell Alexandra Guckes committed
            <p>Following the recommendations from KU Leuven, we have also taken steps to expand our experimental approach. To further investigate the CFTR functionality, we have ordered <a onClick={() => goToPageAndScroll ('Cell Culture', '/materials-methods')}>CFBE41o-</a> as a new cell line from <a onClick={() => goToPagesAndOpenTab('ignatova', '/human-practices')}>Prof. Dr. Ignatova</a> in Hamburg. Our goal is to use these patient-derived cells to measure ion currents and further elucidate the impact of the mutation on chloride conductance. This will not only provide a more clinically relevant model but may also yield more distinct results in comparison to the previous experiments with the engineered HEK293T cells.</p>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
      </Subesction >
      </Section>
      <Section title="Supplementary Material" id="Supplementary Material">    
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
      <p>Supplementary Material for Patch Clamp</p>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
      <p><DownloadLink url="https://static.igem.wiki/teams/5247/pdfs/raw-data-patch-clamp.pdf" fileName="raw-data-patch-clamp.pdf" /></p>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
      <p>Supplementary Material for Delivery</p>
      <DownloadLink url="https://static.igem.wiki/teams/5247/pdfs/raw-data-patch-clamp.pdf" fileName="raw-data-patch-clamp.pdf" />
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed
      </Section>
Isabell Alexandra Guckes's avatar
Isabell Alexandra Guckes committed